A September Skip, The Bullish Case for Viking Therapeutics, and Lassoing the Laggards 8/19/25
- 43m
--:----:--
About this episode
Why the Fed could skip a September cut altogether, despite higher inflation data. BTIG makes the case for sticking with Viking Therapeutics despite disappointing weight loss drug trial data. Plus, the laggards our traders says to buy now.